The research group of Professor Kenji Osafune, our founder and Chief Scientific Advisor, and Program-Specific Junior Associate Professor Toshikazu Araoka, our scientific advisor, has confirmed cell therapy efficacy in mouse model on chronic kidney disease (CKD). Transplantation into model mice showed that it suppressed the decline in renal function and the progression of tissue fibrosis.

The research paper of these findings has been published in ‘Science Translational Medicine’ under the following title.

Paper title:
‘Human iPSC-derived nephron progenitor cells treat AKI and CKD in mouse models’

Link to the published article:
https://www.science.org/doi/10.1126/scitranslmed.adt5553

Our company is developing nephron progenitor cells derived from human iPS cells (RN-032) as a cell therapy for chronic kidney disease. When chronic kidney disease progresses to end-stage renal failure, transitioning to dialysis therapy becomes unavoidable. Currently, there are approximately 786,000 dialysis patients in the U.S., and the annual medical costs are estimated to reach 51 billion USD.

Rege Nephro is committed to providing new treatment options through the research and development of RN-032 for patients suffering from these intractable kidney diseases, and we will continue to dedicate our full efforts to this endeavor.

For more details, please visit the following website of the Center for iPS Cell Research and Application, Kyoto University.
https://www.cira.kyoto-u.ac.jp/j/pressrelease/news/250403-030000.html